SLC19A1 and lymphoma: Based on the limited significant findings and high volume of conflicting evidence, it is unlikely that polymorphisms in SLC19A1 and MTHFR significantly affect high-dose MTX PK in pediatric patients with ALL, osteosarcoma, or lymphoma.